Understanding how the tumor environment affects treatment response in T-cell lymphoma
Official title: Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial Modeling
Funded at Brigham and Women's Hospital · NIH-11032024 · Data updated 2026-11-12
This study is looking at how the arrangement of cells in T-cell lymphoma tumors affects how well treatments work, with the goal of finding new ways to personalize therapy for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 5R00CA256497-05 |
| Project ID | NIH-11032024 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with T-cell lymphoma who are seeking personalized treatment options.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with T-cell lymphoma may not benefit from this research.
What this research studies
This research investigates the role of the tumor ecosystem in T-cell lymphoma, focusing on how the spatial organization of cells within tumors can influence treatment responses. By utilizing advanced imaging techniques and omics technologies, the study aims to identify new predictive biomarkers that can help tailor therapies for patients. The approach involves integrating detailed spatial data with existing genetic information to create more accurate models for predicting patient outcomes. This could lead to more personalized treatment strategies for individuals diagnosed with T-cell lymphoma.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better outcomes for patients with T-cell lymphoma.
How similar studies have gone: Other research has shown promise in using spatial modeling and omics technologies to improve cancer treatment predictions, indicating a potential for success in this approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Nirmal, Ajit Johnson — Brigham and Women's Hospital
- Study coordinator: Nirmal, Ajit Johnson
Related research
Other NIH-funded projects on the same topics.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial
A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
How a rare intestinal T‑cell lymphoma begins
This project will test whether losing the SETD2 gene and turning on certain cancer genes causes a rare intestinal T‑cell lymphoma and makes it more sensitive to chemotherapy for people with MEITL.
-
CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma
This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.